This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Engineering the Therapeutic Window in HER2 Radioligand Therapy: First-in-Human Experience with Affibody molecule ABY-271

Engineering the Therapeutic Window in HER2 Radioligand Therapy: First-in-Human Experience with Affibody molecule ABY-271

12:00 pm - Thursday 23rd July 2026

Clinical translation underway: First-in-human Phase 1 study of HER2-targeted radioligand moving forward with dose escalation
Expanding the therapeutic window: Protein mass-dose optimization to address HER2-low disease
Broadening the radiopharma space: Addressing physiological HER2 expression to unlock new RLT opportunities

Speakers:

Guido Würth

Head of Corporate Development & Radiopharma Medical & Health; Sales; Operations

Affibody AB